Highest-materiality recent filing
Aclaris Therapeutics enters into new at-the-market equity offering agreement with Leerink and Cantor
Second Amended and Restated Sales Agreement with Leerink Partners and Cantor Fitzgerald for at-the-market common stock offerings.
Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing
Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.
Aclaris shareholders elect directors, approve executive pay at 2026 annual meeting
80.55% of shares voted; 112,499,671 of 139,663,680 outstanding shares represented.
Aclaris Q1 net loss widens to $19.8M; positive Phase 1a data for ATI-052
Net loss $19.8M vs $15.1M YoY; revenue $2.0M (+33%) on higher Lilly/Sun Pharma royalties.
ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.
Aclaris Therapeutics sells 5.7M shares for $20M gross proceeds in ATM offering
5.7M shares sold on March 10, 2026 for aggregate gross proceeds of $20.0M.
Aclaris Therapeutics raises $39.8M via ATM offering of 12.7M shares
Sold 12.7 million shares for gross proceeds of $39.8M under ATM agreement from March 2-9, 2026.
Aclaris Q4 net loss $19.8M; cash $151.4M; ATI-052 POC trials underway
Net loss of $19.8M in Q4 2025 vs $96.6M in Q4 2024; full year net loss $64.9M vs $132.1M.
Filed Form 8-K on Jan. 12, 2026, updating its corporate overview presentation (Exhibit 99.1).
ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.
Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates
Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.
Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing
R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.
Aclaris Q2 net loss widens to $15.4M; advances ATI-2138, bosakitug, ATI-052 trials
Net loss $15.4M vs $11.0M YoY; revenue $1.8M, down 36% due to prior royalty sale.
14 patients enrolled; 10 per protocol; no SAEs or discontinuations; well tolerated with mild, transient TRAEs.
Aclaris Therapeutics posts updated corporate presentation; no material changes discernible
Presentation includes corporate strategy and pipeline overview; no financial results or guidance changes disclosed.
Authorized common shares increased from 200M to 400M via Certificate of Amendment effective June 5, 2025; approved by ~96% of votes.
Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.
Aclaris Q4 net loss $96.6M, revenue $9.2M; cash $203.9M; pipeline catalysts in H1 2025
Net loss $96.6M in Q4 2024 vs $1.5M in Q4 2023; included $86.9M in-process R&D charge from bosakitug license.
Aclaris Therapeutics updates corporate presentation; no material new data disclosed
Company posted an updated investor presentation on January 13, 2025.
Aclaris licenses anti-TSLP/IL4R biologics, raises $80M, appoints Davis as President/COO
License deal: $30M upfront, $4.5M dev reimbursement, warrants for 14.3M shares at $0.00001, up to $920M milestones, royalties.
Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028
Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.
Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale
Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.
Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones
Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.
Aclaris shareholders elect two directors, approve say-on-pay, ratify auditor at 2024 annual meeting
Elected Christopher Molineaux (29.2M for, 16.2M withheld) and Vincent Milano (42.3M for, 3.1M withheld) as directors.
Aclaris reports Q1 net loss $16.9M, down 40% YoY; advances ATI-2138 into Phase 2a for AD
Net loss narrowed to $16.9M from $28.2M YoY; total revenue $2.4M, flat.
Two Aclaris directors to depart at 2024 annual meeting
Director Andrew Powell resigns effective June 6, 2024; no disagreement cited.
Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M
Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.
Aclaris discloses interim CEO Neal Walker's compensation: $500k salary, equity awards
Douglas Manion stepped down as CEO/President effective Jan 16, 2024; no disagreement.
Aclaris terminates CMO, enters separation with former CEO; promotes CSO to full-time
Terminated Gail Cawkwell as CMO effective Jan 31, 2024, without cause; receives 12-month salary continuation and COBRA coverage.
Douglas Manion stepped down as CEO/President and Board member effective Jan 16, 2024; mutual decision with no disagreement.
Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024
Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.
Aclaris Phase 2b zunsemetinib fails endpoints; ATI-450 program discontinued
Study of oral MK2 inhibitor zunsemetinib (20mg or 50mg BID) in 251 RA patients did not meet primary endpoint ACR20 at week 12.
Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023
Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.
Aclaris reports positive Phase 1 MAD data for ATI-2138; advances to Phase 2a in ulcerative colitis
ATI-2138 well tolerated in 60-subject MAD trial; no serious adverse events; mild headache and diarrhea only events in >1 subject.
Aclaris Q2 net loss widens to $29.6M; zunsemetinib RA data expected Q4 2023
Net loss $29.6M vs $20.5M YoY; revenue $1.9M vs $1.5M, driven by licensing royalties.
Aclaris CSO Joseph Monahan shifts to part-time; base salary reduced to $280,800
Monahan will serve as Chief Scientific Officer at 60% of full-time schedule as of July 1, 2023.
Aclaris stockholders approve doubling of authorized shares to 200M at annual meeting
Amendment to authorized common stock from 100M to 200M shares approved: 60.7M for, 547K against, 3.4M abstain.
Aclaris Therapeutics signs new HQ lease for 11,564 sq ft in Wayne, PA
Lease with CBCC – Lee Road Acquisitions for space at 701 Lee Road, Wayne, PA.
Aclaris posts Q1 net loss of $28.2M; delays PsA and AD trial data timelines
Net loss widened to $28.2M from $18.8M YoY; revenue rose to $2.5M on higher licensing royalties.
Aclaris updates corporate presentation; no specific financial or pipeline news disclosed
Company furnished an updated corporate overview presentation on April 14, 2023.
Aclaris raises $27.5M via sale of 3.4M shares to Bain Capital affiliates
Sold 3.4M shares of common stock for aggregate gross proceeds of $27.5M.
Aclaris extends former CFO Frank Ruffo's consulting term to June 30, 2023 with $12,500 monthly fee
Consulting term extended from March 3, 2023 through June 30, 2023.
Aclaris Phase 2a zunsemetinib trial for hidradenitis suppurativa fails to meet endpoints
Study did not meet primary endpoint of change in inflammatory nodule/abscess count at week 12.
Aclaris Therapeutics enters $200M ATM equity facility, terminates prior $150M ATM
New Sales Agreement with SVB Securities and Cantor Fitzgerald for up to $200M in common stock at-the-market.
Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025
Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.
Aclaris presents at J.P. Morgan Healthcare Conference on Jan 11; no material financial updates
Management presents company overview and slide deck at 41st Annual J.P. Morgan Healthcare Conference on Jan 11, 2023.
Aclaris finalizes CEO and CFO employment agreements; Manion $600k base, Balthaser $444k base
Douglas Manion appointed CEO effective Jan 1, 2023 with annual base salary of $600,000 and target bonus of 55% of base.
Aclaris Therapeutics enters separation agreement with retiring executive Frank Ruffo
Frank Ruffo's retirement separation agreement approved; includes consulting deal through March 2, 2023 for $25,000.
Neal Walker resigns as CEO effective Dec 31, 2022; appointed Chair of the Board effective Jan 1, 2023.
Aclaris Q3 net loss $20M, revenue $19M on $17.6M Lilly license; ATI-2138 Phase 1 SAD positive
Net loss of $20.0M for Q3 2022 vs $21.1M in Q3 2021; operating loss offset by $17.6M licensing revenue from Lilly alopecia areata patent deal.
The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director
In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.
On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.
On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).
Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.
On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement
On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.
in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.
On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.
the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.
On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.
Dr. Monahan will continue to serve as the Company’s Chief Scientific Officer but will shift to part-time status, pursuant to which he will provide services at 60% of a full-time schedule.
Max materiality 0.90 · Median 0.65 · Most common event other_material